comparemela.com


Home > Press > Nanotechnology -- nanoparticles as weapons against cancer
The amorphous nanoparticles dissolve very efficiently in the cell. Source: von Schirnding et al., Chem 2020
Abstract:
Many chemotherapeutic agents used to treat cancers are associated with side-effects of varying severity, because they are toxic to normal cells as well as malignant tumors. This has motivated the search for effective alternatives to the synthetic pharmaceuticals with which most cancers are currently treated. The use of calcium phosphate and citrate for this purpose has been under discussion for some years now, since they lead to cell death when delivered directly into cells, while their presence in the circulation has little or no toxic effect. The problem consists in finding ways to overcome the mechanisms that control the uptake of these compounds into cells, and ensuring that the compounds act selectively on the cells one wishes to eliminate. Researchers in the Department of Chemistry at LMU, led by Dr. Constantin von Schirnding, Dr. Hanna Engelke and Prof. Thomas Bein, now report the development of a class of novel amorphous nanoparticles made up of calcium and citrate, which are capable of breaching the barriers to uptake, and killing tumor cells in a targeted fashion.

Related Keywords

Munich ,Bayern ,Germany ,Schirnding ,Hanna Engelke ,Dipanjan Pan ,Constanze Drewlo ,Department Of Chemistry ,Arrowhead Pharmaceuticals Announces Closing Of Agreement ,Home Press Nanotechnology ,Arrowhead Pharmaceuticals To Participate In Upcoming Conferences ,Rice University ,Wave Inc ,Thomas Bein ,Nanotechnology Now ,Upcoming Conferences December ,Pharmaceuticals Announces Closing ,Takeda November ,முனிச் ,பேயர்ன் ,ஜெர்மனி ,டிபன்ஜன் பான் ,துறை ஆஃப் வேதியியல் ,வீடு ப்ரெஸ் நானோ தொழில்நுட்பம் ,அம்புக்குறி மருந்துகள் க்கு பங்கேற்க இல் வரவிருக்கும் மாநாடுகள் ,அரிசி பல்கலைக்கழகம் ,அலை இன்க் ,தாமஸ் பெயின் ,நானோ தொழில்நுட்பம் இப்போது ,வரவிருக்கும் மாநாடுகள் டிசம்பர் ,டாகேடா நவம்பர் ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.